专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050084485A1 Clckb mutation as a diagnostic and therapeutical target 失效
标题翻译： Clckb突变作为诊断和治疗靶点
公开(公告)号：US20050084485A1
公开(公告)日：2005-04-21
申请号：US10687523
申请日：2003-10-15
申请人： Florian Lang , Siegfried Waldegger , Philipp Lang , Angelika Lampert , Hannsjoerg Seybert , Nikola Jeck
发明人： Florian Lang , Siegfried Waldegger , Philipp Lang , Angelika Lampert , Hannsjoerg Seybert , Nikola Jeck
IPC分类号： C12Q1/68 , A61K38/48 , C07H21/04 , C12N9/12
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention relates to a method for diagnosing hypertension, and/or allergy, and/or hair loss, and/or liabilty for infection, of a human being, or a predisposition therefor; to a nucleic acid molecule coding for a human ClCKb protein comprising a genetic alteration at amino acid position 481 compared to the wild type, as well as for corresponding segments thereof; to a nucleic acid molecule which binds to the before-mentioned nucleic acid molecule under stringent conditions, as well as to a nucleic acid molecule which binds to that nucleic acid molecule; to a (poly)peptide encoded by the afore-mentioned nucleic acid molecules; to a method for identifying substances modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to the wild type; to a substance for modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to the wild type; to methods for preparing a pharmaceutical composition for treatment of hypertension, and/or allergy, and/or hair loss, and/or liability for infection; to pharmaceutical compositions; and to a method for treating a human being affected by hypertension, and/or allergy and/or hair loss, and/or liability for infection.
摘要翻译：本发明涉及一种用于诊断人类或其易感性的高血压，/或过敏和/或脱发，和/或感染的可能性的方法; 涉及编码人类ClCKb蛋白质的核酸分子，其包含与野生型相比在氨基酸位置481处的遗传改变，以及其对应的片段; 涉及在严格条件下与前述核酸分子结合的核酸分子，以及与该核酸分子结合的核酸分子; 涉及由上述核酸分子编码的（多）肽; 涉及一种用于鉴定与野生型相比在氨基酸位置481遗传改变的来自ClCKb蛋白的肽调节活性的物质的方法; 涉及调节与野生型相比在氨基酸位置481遗传改变的来自ClCKb蛋白的肽的活性的物质; 制备用于治疗高血压和/或过敏和/或脱发的药物组合物和/或感染责任的方法; 至药物组合物; 以及治疗受高血压，/或过敏和/或脱发影响的人的方法和/或感染责任。

2. 发明授权

US06326181B1 Cell volume-regulated human kinase h-sgk 失效
标题翻译：细胞体积调节人激酶h-sgk
公开(公告)号：US06326181B1
公开(公告)日：2001-12-04
申请号：US09031295
申请日：1998-02-26
申请人： Florian Lang , Siegfried Waldegger
发明人： Florian Lang , Siegfried Waldegger
IPC分类号： C12N912
CPC分类号： C12N9/1205 , A61K38/00
摘要： The present invention relates to the cloning and characterization of a human serine/threonine kinase (h-sgk: serum and glucocorticoid dependent kinase). The invention furthermore relates to reagents for diagnosing conditions associated with a change in cell volume and/or in “macromolecular crowding” in the body, such as, for example, hypernatremia, hyponatremia, diabetes mellitus, renal failure, hypercatabolism, hepatic encephalopathy, inflammation and microbial or viral infections. The present invention additionally relates to pharmaceuticals comprising the h-sgk, nucleic acids which code for the h-sgk, or receptors, in particular antibodies, which specifically bind to the h-sgk.
摘要翻译：本发明涉及人丝氨酸/苏氨酸激酶（h-sgk：血清和糖皮质激素依赖性激酶）的克隆和表征。本发明还涉及用于诊断与细胞体积变化和/或体内“大分子拥挤”相关的病症的试剂，例如高钠血症，低钠血症，糖尿病，肾功能衰竭，高分泌症，肝性脑病，炎症和微生物或病毒感染。本发明还涉及包含h-sgk，编码h-sgk的核酸或特异性结合h-sgk的受体，特别是抗体的药物。

3. 发明授权

US07235364B2 CICKb mutation as a diagnostic and therapeutical target 失效
标题翻译： CICKB突变作为诊断和治疗靶点
公开(公告)号：US07235364B2
公开(公告)日：2007-06-26
申请号：US11398208
申请日：2006-04-04
申请人： Florian Lang , Siegfried Waldegger , Philipp Lang , Angelika Lampert , Hannsjoerg Seybert , Nikola Jeck
发明人： Florian Lang , Siegfried Waldegger , Philipp Lang , Angelika Lampert , Hannsjoerg Seybert , Nikola Jeck
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention relates to a method for diagnosing hypertension, and/or allergy, and/or hair loss, and/or liabilty for infection, of a human being, or a predisposition therefor; to a nucleic acid molecule coding for a human ClCKb protein comprising a genetic alteration at amino acid position 481 compared to the wild type, as well as for corresponding segments thereof; to a nucleic acid molecule which binds to the before-mentioned nucleic acid molecule under stringent conditions, as well as to a nucleic acid molecule which binds to that nucleic acid molecule; to a (poly)peptide encoded by the afore-mentioned nucleic acid molecules; to a method for identifying substances modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to the wild type; to a substance for modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to the wild type; to methods for preparing a pharmaceutical composition for treatment of hypertension, and/or allergy, and/or hair loss, and/or liability for infection; to pharmaceutical compositions; and to a method for treating a human being affected by hypertension, and/or allergy and/or hair loss, and/or liability for infection.
摘要翻译：本发明涉及一种用于诊断人类或其易感性的高血压，/或过敏和/或脱发，和/或感染的可能性的方法; 涉及编码人类ClCKb蛋白质的核酸分子，其包含与野生型相比在氨基酸位置481处的遗传改变，以及其对应的片段; 涉及在严格条件下与前述核酸分子结合的核酸分子，以及与该核酸分子结合的核酸分子; 涉及由上述核酸分子编码的（多）肽; 涉及一种用于鉴定与野生型相比在氨基酸位置481遗传改变的来自ClCKb蛋白的肽调节活性的物质的方法; 涉及调节与野生型相比在氨基酸位置481遗传改变的来自ClCKb蛋白的肽的活性的物质; 制备用于治疗高血压和/或过敏和/或脱发的药物组合物和/或感染责任的方法; 至药物组合物; 以及治疗受高血压，/或过敏和/或脱发影响的人的方法和/或感染责任。

4. 发明申请

US20050064501A1 Medicaments comprising inhibitors of the cell volume-regulated human kinase h-sgk 审中-公开
标题翻译：包含细胞体积调节人激酶h-sgk的抑制剂的药物
公开(公告)号：US20050064501A1
公开(公告)日：2005-03-24
申请号：US10984945
申请日：2004-11-10
申请人： Florian Lang , Siegfried Waldegger , Carsten Wagner , Stefan Broer , Karin Klingel
发明人： Florian Lang , Siegfried Waldegger , Carsten Wagner , Stefan Broer , Karin Klingel
IPC分类号： A61K31/00 , A61K31/4741 , A61K31/553 , A61K38/00 , C12Q1/68
CPC分类号： A61K31/4741 , A61K31/00 , A61K31/553 , A61K38/005
摘要： The present invention relates to medicaments comprising inhibitors or activators of the cell volume-regulated human kinase h-sgk. Such medicaments are suitable for the therapy of pathological states in which an increased or reduced expression of h-sgk is found.
摘要翻译：本发明涉及包含细胞体积调节人激酶h-sgk的抑制剂或活化剂的药物。这种药物适用于治疗h-sgk表达增加或减少的病理状态。

5. 发明授权

US06855520B2 Cell volume-regulated human kinase h-sgk 失效
公开(公告)号：US06855520B2
公开(公告)日：2005-02-15
申请号：US10000039
申请日：2001-12-04
申请人： Florian Lang , Siegfried Waldegger
发明人： Florian Lang , Siegfried Waldegger
IPC分类号： G01N33/573 , A61K31/70 , A61K38/00 , A61K39/395 , A61P13/02 , A61P15/00 , C07K14/705 , C12N9/12 , C12N15/02 , C12N15/54 , C12P21/08 , C12Q1/68 , G01N33/577 , C12P19/30 , C07H21/02 , C07H21/04 , C12P19/34
CPC分类号： C12N9/1205 , A61K38/00
摘要： The present invention relates to the cloning and characterization of a human serine/threonine kinase (h-sgk: serum and glucocorticoid dependent kinase). The invention furthermore relates to reagents for diagnosing conditions associated with a change in cell volume and/or in “macromolecular crowding” in the body, such as, for example, hypernatremia, hyponatremia, diabetes mellitus, renal failure, hypercatabolism, hepatic encephalopathy, inflammation and microbial or viral infections. The present invention additionally relates to pharmaceuticals comprising the h-sgk, nucleic acids which code for the h-sgk, or receptors, in particular antibodies, which specifically bind to the h-sgk.

6. 发明申请

US20060240459A1 ClCKb mutation as a diagnostic and therapeutical target 失效
标题翻译： ClCKb突变作为诊断和治疗靶点
公开(公告)号：US20060240459A1
公开(公告)日：2006-10-26
申请号：US11398208
申请日：2006-04-04
申请人： Florian Lang , Siegfried Waldegger , Philipp Lang , Angelika Lampert , Hannsjoerg Seybert , Nikola Jeck
发明人： Florian Lang , Siegfried Waldegger , Philipp Lang , Angelika Lampert , Hannsjoerg Seybert , Nikola Jeck
IPC分类号： C12Q1/68 , C07H21/04 , C12P21/06 , C12N9/12 , A61K48/00
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention relates to a method for diagnosing hypertension, and/or allergy, and/or hair loss, and/or liabilty for infection, of a human being, or a predisposition therefor; to a nucleic acid molecule coding for a human ClCKb protein comprising a genetic alteration at amino acid position 481 compared to the wild type, as well as for corresponding segments thereof; to a nucleic acid molecule which binds to the before-mentioned nucleic acid molecule under stringent conditions, as well as to a nucleic acid molecule which binds to that nucleic acid molecule; to a (poly)peptide encoded by the afore-mentioned nucleic acid molecules; to a method for identifying substances modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to the wild type; to a substance for modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to the wild type; to methods for preparing a pharmaceutical composition for treatment of hypertension, and/or allergy, and/or hair loss, and/or liability for infection; to pharmaceutical compositions; and to a method for treating a human being affected by hypertension, and/or allergy and/or hair loss, and/or liability for infection.
摘要翻译：本发明涉及一种用于诊断人类或其易感性的高血压，/或过敏和/或脱发，和/或感染的可能性的方法; 涉及编码人类ClCKb蛋白质的核酸分子，其包含与野生型相比在氨基酸位置481处的遗传改变，以及其对应的片段; 涉及在严格条件下与前述核酸分子结合的核酸分子，以及与该核酸分子结合的核酸分子; 涉及由上述核酸分子编码的（多）肽; 涉及一种用于鉴定与野生型相比在氨基酸位置481遗传改变的来自ClCKb蛋白的肽调节活性的物质的方法; 涉及调节与野生型相比在氨基酸位置481遗传改变的来自ClCKb蛋白的肽的活性的物质; 制备用于治疗高血压和/或过敏和/或脱发的药物组合物和/或感染责任的方法; 至药物组合物; 以及治疗受高血压，/或过敏和/或脱发影响的人的方法和/或感染责任。

7. 发明授权

US07074573B2 CLCKb mutation as a diagnostic therapeutical target 失效
标题翻译： CLCKb突变作为诊断性治疗靶点
公开(公告)号：US07074573B2
公开(公告)日：2006-07-11
申请号：US10687523
申请日：2003-10-15
申请人： Florian Lang , Siegfried Waldegger , Phillipp Lang , Angelika Lampert , Hannsjoerg Seybert , Nikola Jeck
发明人： Florian Lang , Siegfried Waldegger , Phillipp Lang , Angelika Lampert , Hannsjoerg Seybert , Nikola Jeck
IPC分类号： G01N33/53 , C07K14/00
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention relates to a method for diagnosing hypertension, and/or allergy, and/or hair loss, and/or liability for infection, of a human being, or a predisposition therefor; to a nucleic acid molecule coding for a human ClCKb protein comprising a genetic alteration at amino acid position 481 compared to the wild type, as well as for corresponding segments thereof; to a nucleic acid molecule which binds to the before-mentioned nucleic acid molecule under stringent conditions, as well as to a nucleic acid molecule which binds to that nucleic acid molecule; to a (poly)peptide encoded by the afore-mentioned nucleic acid molecules; to a method for identifying substances modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to the wild type; to a substance for modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to the wild type; to methods for preparing a pharmaceutical composition for treatment of hypertension, and/or allergy, and/or hair loss, and/or liability for infection; to pharmaceutical compositions; and to a method for treating a human being affected by hypertension, and/or allergy and/or hair loss, and/or liability for infection.
摘要翻译：本发明涉及一种用于诊断人类或其易感性的高血压，/或过敏和/或脱发，和/或感染责任的方法; 涉及编码人类ClCKb蛋白质的核酸分子，其包含与野生型相比在氨基酸位置481处的遗传改变，以及其对应的片段; 涉及在严格条件下与前述核酸分子结合的核酸分子，以及与该核酸分子结合的核酸分子; 涉及由上述核酸分子编码的（多）肽; 涉及一种用于鉴定与野生型相比在氨基酸位置481遗传改变的来自ClCKb蛋白的肽调节活性的物质的方法; 涉及调节与野生型相比在氨基酸位置481遗传改变的来自ClCKb蛋白的肽的活性的物质; 制备用于治疗高血压和/或过敏和/或脱发的药物组合物和/或感染责任的方法; 至药物组合物; 以及治疗受高血压，/或过敏和/或脱发影响的人的方法和/或感染责任。

8. 发明申请

US20050181402A1 Cell volume-regulated human kinase h-sgk 审中-公开
标题翻译：细胞体积调节人激酶h-sgk
公开(公告)号：US20050181402A1
公开(公告)日：2005-08-18
申请号：US11044570
申请日：2005-01-28
申请人： Florian Lang , Siegfried Waldegger
发明人： Florian Lang , Siegfried Waldegger
IPC分类号： G01N33/573 , A61K31/70 , A61K38/00 , A61K39/395 , A61P13/02 , A61P15/00 , C07K14/705 , C12N9/12 , C12N15/02 , C12N15/54 , C12P21/08 , C12Q1/68 , G01N33/577 , C07H21/04 , C07K16/40 , G01N33/53 , G01N33/567
CPC分类号： C12N9/1205 , A61K38/00
摘要： The present invention relates to the cloning and characterization of a human serine/threonine kinase (h-sgk: serum and glucocorticoid dependent kinase). The invention furthermore relates to reagents for diagnosing conditions associated with a change in cell volume and/or in “macromolecular crowding” in the body, such as, for example, hypernatremia, hyponatremia, diabetes. mellitus, renal failure, hypercatabolism, hepatic encephalopathy, inflammation and microbial or viral infections. The present invention additionally relates to pharmaceuticals comprising the h-sgk, nucleic acids which code for the h-sgk, or receptors, in particular antibodies, which specifically bind to the h-sgk.
摘要翻译：本发明涉及人丝氨酸/苏氨酸激酶（h-sgk：血清和糖皮质激素依赖性激酶）的克隆和表征。本发明还涉及用于诊断与细胞体积变化和/或体内“大分子拥挤”相关的病症的试剂，例如高钠血症，低钠血症，糖尿病。肾功能衰竭，高分泌症，肝性脑病，炎症和微生物或病毒感染。本发明还涉及包含h-sgk，编码h-sgk的核酸或特异性结合h-sgk的受体，特别是抗体的药物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式